key: cord-0804244-jajbpkk2
authors: Ebner, Benedikt; Volz, Yannic; Mumm, Jan-Niclas; Stief, Christian G.; Magistro, Giuseppe
title: The COVID-19 pandemic — what have urologists learned?
date: 2022-04-13
journal: Nat Rev Urol
DOI: 10.1038/s41585-022-00586-1
sha: bc7cf14477f458d2e8a04cdac0d75bb8736b20c9
doc_id: 804244
cord_uid: jajbpkk2

On 11 March 2020, the WHO declared the coronavirus disease 2019 (COVID-19) outbreak a pandemic and COVID-19 emerged as one of the biggest challenges in public health and economy in the twenty-first century. The respiratory tract has been the centre of attention, but COVID-19-associated complications affecting the genitourinary tract are reported frequently, raising concerns about possible long-term damage in these organs. The angiotensin-converting enzyme 2 (ACE2) receptor, which has a central role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invasion, is highly expressed in the genitourinary tract, indicating that these organs could be at a high risk of cell damage. The detection of SARS-CoV-2 in urine and semen is very rare; however, COVID-19 can manifest through urological symptoms and complications, including acute kidney injury (AKI), which is associated with poor survival, severe structural changes in testes and impairment of spermatogenesis, and hormonal imbalances (mostly secondary hypogonadism). The effect of altered total testosterone levels or androgen deprivation therapy on survival of patients with COVID-19 was intensively debated at the beginning of the pandemic; however, androgen inhibition did not show any effect in preventing or treating COVID-19 in a clinical study. Thus, urologists have a crucial role in detecting and managing damage of the genitourinary tract caused by COVID-19.

virus 19 . At this point, transmembrane protease serine 2 (TMPRSS2) is responsible for the cleavage of spike proteins (defined as 'priming'), which is required for fusion of cellular and viral membranes 20 (fig. 1 ). Interestingly, TMPRSS2 is a crucial factor in the pathogenesis of SARS-CoV-2, and also an important regulator in prostate cancer 21, 22 . TMPRSS2 is, in fact, predominantly expressed in prostate epithelium 23 and is upregulated in prostate cancer with high Gleason grades 24 . Moreover, the risk of viral invasion in different tissues was hypothesized to be dependent on the expression level of ACE2 (ref. 25 ). Results from a single-cell RNA-sequencing study in which datasets from different organs were analysed showed that the average proportion of ACE2 + type II alveolar cells in the lungs was ~1%, with 1% standard deviation 17 . On this basis, cell types with >1% of ACE2 + cells were considered at a 'high risk' of SARS-CoV-2 infection. High ACE2 expression levels were found in kidney proximal tubule cells (4% positivity) and in bladder urothelial cells (2.4% positivity) 17 . However, the investigators emphasized that gene expression variation between individuals should also be considered and that SARS-CoV-2 invasion does not exclusively depend on ACE2. Thus, the existence, in kidney and bladder, of a higher risk of cell damage than other organs remains unclear 17 (fig. 2 ). In another study in which transcriptome data from published single-cell RNA-sequencing studies was analysed, high expression levels of ACE2 and TMPRSS2 in kidney and testis tissue were reported 18 . However, to date, no clear proof is available to support the original hypothesis that high ACE2 expression levels increase the risk of viral invasion. In fact, high activity of ACE2 has also been postulated to be potentially beneficial for patients with COVID-19 by diminishing lung injury and inflammation 26 . ACE2 is, indeed, also a major component of the renin-angiotensin-aldosterone system (RAAS) 27 , a crucial regulatory system for fluid and electrolyte balance, systemic vascular resis tance and, thereby, blood pressure 28 . ACE2 converts angiotensin II, which is a main perpetrator of inflammation, into angiotensin 1-7, which has anti-inflammatory properties 27 . Thus, ACE2 might have a double role in COVID-19: pro-infection, acting as a cellular receptor for SARS-CoV-2, and protective during SARS-CoV-2 infection, by mitigating inflammation 26, 29 .

Thus, the discussion on the effects of RAAS blockers on the outcome of patients with COVID-19 has been quite controversial 26 ; however, drugs targeting the RAAS have shown no relevant improvements in the risk of COVID-19 infection and disease outcome 30 .

Acute kidney injury in COVID- 19 The reported incidence of acute kidney injury (AKI) in patients with COVID-19 is heterogeneous and ranges from 1% to 46% 31 . Results from a big retrospective, observational study analysing the incidence of AKI in 3,993 hospitalized patients with COVID-19 showed that AKI occurred in 46% of patients 32 ; 19% of whom required kidney replacement therapy 32 . The mortality was 50% in patients with AKI and 8% in patients without AKI 32 . Moreover, only ~30% of patients who survived showed a recovery of kidney function at the time of discharge 32 . Thus, AKI in patients with COVID-19 is common and associated with high mortality; recovery of kidney function is delayed or absent in many patients with AKI. AKI was reported to be the most common complication of COVID-19 in a multicentre cohort study including 80,388 patients with COVID-19 (ref. 33 ). However, in another prospective multicentre cohort study including 85,687 patients, only 2,198 patients (2.6%) received kidney replacement therapy 34 , indicating that the need for this therapy in patients with COVID-19 and AKI might be lower than previously suggested 32 . In a prospective cohort study including 701 patients with COVID-19, 43.9% had proteinuria and 26.7% had haematuria on admission, indicating severe damage of kidney tissue 35 . Patients with highly prevalent risk factors, such as diabetes, obesity or hypertension, are at an increased risk of developing SARS-CoV-2-mediated AKI (adjusted odds ratio (OR): 1.76 for diabetes, 1.11 for obesity and 1.25 for hypertension) 36, 37 . The reported mortality in hospitalized patients with COVID-19 and AKI varies tremendously (34-80%) 36 , but might still be considered substantially higher than the average mortality of all hospitalized patients with COVID-19 (including patients without AKI), reported to be between 9.3% and 19.7% in a cohort study including 503,409 patients 38 . The rate of AKI correlates with the classification of COVID-19 disease severity by the WHO, as AKI has been observed in 3.2%, 15.2% and 24.3% of patients with moderate COVID-19, severe COVID-19 and acute respiratory distress syndrome, respectively, in a prospective assessment of 333 patients with COVID-19 (ref. 39 ). AKI in patients with COVID-19 also correlates with patients' history of chronic kidney disease (CKD) 39 . In a case series of 7,624 patients with COVID-19, the reported mortality was 23.1% in patients with CKD and 10.2% in patients without CKD (P < 0.001), with odds of mortality 1.51 times higher (95% CI 1. 19-1.90) in patients with CKD than in the non-CKD group 40 .

Pathophysiological mechanisms leading to AKI development in patients with COVID-19 have not

• High expression levels of the angiotensin-converting enzyme 2 (ACE2) receptor, which has a central role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invasion, can be found in the genitourinary tract, especially in kidney proximal tubule cells, bladder urothelial cells and testes. • Acute kidney injury (AKI) occurs frequently in patients with coronavirus disease 2019 and is the most common complication of COVID-19. Cytokine-storminduced systemic inflammatory response and direct cytopathic effects are possible pathophysiological mechanisms of AKI. • The detection of SARS-CoV-2 in urine is rare, although the virus can be detected in urine up to 52 days after disease onset. SARS-CoV-2 is rarely detected in semen. • Results of autopsy studies have shown severe structural changes in testes of deceased patients with COVID-19. An acute impairment of spermatogenesis in patients with COVID-19 is probably caused by fever; however, the existence of long-term effects of COVID-19 on fertility, as observed in other viral orchitides, is still conceivable. • Low levels of total testosterone in patients with COVID-19 are reported frequently, and hypogonadism is often secondary. The effect of androgen deprivation therapy on COVID-19 survival is still debated. • COVID-19-associated coagulopathy can cause endothelial damage and vasculitis, potentially leading to thromboembolism, which also affects urogenital organs.

www.nature.com/nrurol 0123456789();:

yet been fully elucidated and are probably multifactorial. Severe structural changes can be detected in kidney biopsy samples from patients with COVID-19 (refs 41,42 ). In a study analysing kidney biopsy samples from 14 patients with COVID-19, 5 patients had collapsing glomerulopathy, 1 had minimal change disease, 2 had membranous glomerulopathy, 1 had crescentic transformation of lupus nephritis, 1 had anti-glomerular basement membrane nephritis and 4 had isolated acute tubular injury 41 . In another study, post-mortem kidneys from 42 patients who died of COVID-19 were examined, and acute tubular injury was the most common kidney alteration (detected in 45% of patients) 42 . Two instances of acute necrotizing glomerulonephritis associated with COVID-19 have also been described in children 43 .

One of the biggest studies in which histopathological changes in kidney tissue in patients with COVID-19 have been evaluated is an international multicentre retrospective cohort study, including 284 patients with COVID-19 and kidney symptoms (AKI, acute on CKD or protein uria) 44 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin-converting enzyme 2 (ACE2; step 1 in the left and right panels) on the host-cell membrane and undergoes a conformational change in the spike protein subunit 1 (S1) leading to exposure of the S2′ cleavage site in the S2 subunit of the virus; these cleavage events in the two spike proteins of the virus are necessary for the virus entry process. Two viral entry pathways (endosomal and cell surface) are available. Left: in the case of insufficient transmembrane protease serine 2 (TMPRSS2) levels on the host cell, or if a virus-ACE2 complex does not encounter TMPRSS2, the virus-ACE2 complex is internalized via clathrin-mediated endocytosis (step 2) into the endolysosomal compartment, where S2′ is cleaved by the enzymes cathepsins, working in an acidic environment (steps 3 and 4). Right: in the presence of TMPRSS2, S2′ is cleaved at the cell surface (step 2). In both entry pathways, cleavage of the S2′ site exposes the fusion peptide (FP) and induces dissociation of S1 from S2. A dramatic conformational change in the S2 subunit moves the FP forward into the target membrane, initiating membrane fusion (step 5 on the left and step 3 on the right). After the fusion between viral and cellular membranes, viral RNA is released into the host-cell cytoplasm through a fusion pore and viral RNA uncoating occurs (step 6 on the left and step 4 on the right). Several agents disrupt the interaction between the S proteins and ACE2, such as ACE2 mimetics, therapeutic antibodies (targeting S protein) and vaccine-elicited antibodies (blocking the virus binding to ACE2). Other strategies target post-receptor-binding steps: the serine protease inhibitor camostat mesylate acts on TMPRSS2, blocking the TMPRSS2-mediated entry pathway; hydroxychloroquine and chloroquine block endosomal acidification, which is necessary for cathepsin activity, acting on the cathepsin-mediated entry pathway. Reprinted from ref. 19 , Springer Nature Limited. biopsy samples, not significantly different from what was detected in pre-COVID-19 biopsy samples (11.9%, P = 0.52 for native biopsy samples and 17.7%, P = 0.09 for allograft biopsy samples) 44 . The most common finding in native biopsy samples (25.8% of patients) was collapsing glomerulopathy, also known as COVID-19associated nephropathy (COVAN) 44 . The G1 and G2 alleles of the apolipoprotein L1 (APOL1), which are very frequent in men with African ancestry and greatly increase the risk of multiple types of kidney disease 45 , were found in 91.7% of the tested kidney biopsy samples from African American and Hispanic patients with COVAN 44 . Thus, whether the glomerular changes observed in this population (African American and Hispanic patients with COVID-19 who express the G1 and G2 risk alleles of APOL1) are a direct consequence of SARS-CoV-2 infection or emerge as a form of a 'second hit' additional to a pre-existing risk factor is still unclear 46 . Analysis of biopsy samples from patients with kidney allograft showed that allograft rejection disproportionately affected patients with COVID-19 (61.4% versus 27.1% in allograft biopsy samples from the pre-COVID-19 database, P < 0.001) 44 . Taken together, these results show that a wide spectrum of pathological changes in kidney could be detected in patients with COVID-19, with COVAN being the most common diagnosis in native biopsy samples 44 ; moreover, patients with COVID-19 who have a kidney transplant seem to be at a considerable risk of developing an allograft rejection 44 . In this study, no evidence of direct SARS-CoV-2 infection was found in the examined kidney biopsy samples 44 , whereas, in other studies, the virus could be detected in some kidney samples, although this event seems to be rare and depends on the method of detection. However, understanding the viral load in kidney tissue might help to clarify whether the alterations in kidney observed in patients with COVID-19 are caused by the viral infection or occur in response to systemic inflammation.

One possible pathophysiological mechanism of AKI in COVID-19 is a cytokine-storm-induced systemic inflammatory response 31, 41 . A cytokine storm is characterized by an excessive and maladaptive release of pro-inflammatory cytokines during an inflammatory response, which can lead to excessive organ dysfunction 47 . SARS-CoV-2 might cause inflammatory cytokine storms, which lead to acute respiratory distress syndrome or multiple-organ failure and could be associated with disease severity [48] [49] [50] . Results from a study including 41 hospitalized patients with COVID-19 showed higher plasma concentration of multiple cytokines, such as IL-2, IL-7, IL-10, granulocyte colonystimulating factor (G-CSF) and tumour necrosis factor (TNF) in patients treated in the intensive care unit (ICU) 51 than in patients in the non-ICU group 48 . In another study, the concentration of numerous cytokines was significantly higher in patients with COVID-19 (n = 44) than in healthy individuals (n = 66, P < 0.05) and cytokine levels were shown to be associated with different extents of COVID-19 severity 52 . However, no single definition for the term cytokine storm is widely accepted and the line between a normal and a dysregulated response to a severe infection is blurred 47 .

Another mechanism of COVID-19-mediated AKI might be the induction of structural changes in host cells 31 . ACE2 is highly expressed in renal tubular cells, and SARS-CoV-2 has been shown to be able to bind to ACE2 on the surface of these cells in in vitro studies 53, 54 . Results from a single-cell transcriptome analysis of 15 kidney samples from healthy individuals showed co-expression of ACE2 and TMPRSS in the kidney, especially in proximal tubular cells and podocytes 55 . The co-expression level of ACE2 and TMPRSS in these cells was similar to that observed in the lung, supporting the hypothesis that the kidney might be a main target organ for SARS-CoV-2 (ref. 55 ). Podocytes have a crucial role in urine filtration, and proteinuria has been observed in patients with COVID-19 (44% of patients (n = 701) in a prospective study) 35 . Thus, based on the high level of ACE2 and TMPRSS co-expression in podocytes, the investigators concluded that proteinuria in patients with COVID-19 might be caused by a direct cytopathic effect of SARS-CoV-2 on podocytes 55 . Evidence for ACE2-independent cell damage in kidney cells has also been reported. In kidney epithelial cells, a novel route of viral invasion for SARS-CoV-2 mediated by the interaction of spike proteins with CD147 (a transmembrane glycoprotein also known as basigin) has been described 56, 57 , suggesting that other ACE2-independent mechanisms of viral invasion in the kidney might exist and warrant further investigation.

In summary, AKI is a serious and frequently reported complication in patients with COVID-19 (ref. 31 ), but the pathophysiological background of AKI is not fully understood. A wide range of severe pathological changes can be found in kidney tissue samples from patients with COVID-19 (refs 41,42,44 ), but whether this damage is caused by an exuberant systemic inflammatory Results from a single-cell RNA-sequencing study showed that the average proportion of angiotensin-converting enzyme 2 (ACE2)-positive type II alveolar cells in the lungs was ~1%, with 1% standard deviation 17 . On this basis, cell types with >1% of ACE2 + cells were defined as being at a 'high risk' of SARS-CoV-2 infection 17 . High ACE2 expression levels were found in kidney proximal tubule cells (4% ACE2 + cells) and in bladder urothelial cells (2.4% ACE2 + cells); the percentage of ACE2 + cells in these compartments was even higher than that observed in respiratory epithelial cells (2.0% ACE2 + cells) 17 .

www.nature.com/nrurol response 31, 41, [48] [49] [50] 52 or by a direct cytopathic effect of SARS-CoV-2 (refs 31,53-55 ) is still unclear. However, physicians should consider COVID-19 as a potential diagnosis for patients showing fever and signs of AKI.

The detection of SARS-CoV-2 in urine is very rare. In a meta-analysis of 93 studies in which urine samples from 533 patients with COVID-19 were analysed, the presence of SARS-CoV-2 in urine was reported in only 14 studies, in 24 patients in total (4.5%) 58 . In most studies, the urinary SARS-CoV-2 viral load was lower than that observed in oropharyngeal or rectal samples 58 . However, SARS-CoV-2 was detected in urine up to 52 days after disease onset, indicating that the virus might be detectable in urine in the acute stage of COVID-19 and also after recovery 58 . In adults, SARS-CoV-2 was more likely to be found in the urine samples of patients with moderate or severe disease 58 . These observations could suggest either that the viral load of SARS-CoV-2 in the urogenital tract is low or that the viral excretion via the urogenital tract is highly restricted. SARS-CoV-2 could also be unstable in urine, but a PCR test should still detect it.

The detection of SARS-CoV-2 in mucous membranes seems to be dependent on the region tested 59, 60 . SARS-CoV-2 can be detected in anal swabs and in some patients, the test remained positive even when throat swabs and sputum swabs were negative 59 . Thus, this method has been also discussed as a possible tool to evaluate hospital discharge of patients with COVID-19 (ref. 59 ). The situation seems to be different for urethral swabs: in a case series, all ten of the patients tested had a negative urethral swab for SARS-CoV-2 RNA, despite having a positive rhino-oropharyngeal test 60 .

In a meta-analysis of eight studies including 160 semen samples from patients with COVID-19, SARS-CoV-2 was only detected in six patients from one study 61 . The presence of SARS-Cov-2 viral RNA in ejaculate has only been reported in four studies to date 62-65 (6.66% 62 , 15.8% 63 , 2.3% 64 and 14.3% 65 of patients). During sexual intercourse, COVID-19 infection through respiratory droplets is of course possible, but, according to the available data, a sexual transmission of SARS-Cov-2 via semen seems to be very unlikely 66 Overall, these results indicate that detection of SARS-CoV-2 in urine and semen is possible, but is a rare event 58,61-65 .

Cystitis and lower urinary tract symptoms Viral cystitides dependent on SARS-CoV-2 infection have been observed since the beginning of the pandemic, with a high urinary frequency observed in 7 of 57 men with COVID-19, who had no signs of AKI, bacterial infection or prostatitis 67 . De novo urinary symptoms associated with COVID-19, such as increased urinary frequency and nocturia, were also reported in another study including SARS-CoV-2-positive outpatients (n = 39) 68 . A bacterial urinary tract infection in these patients was excluded; therefore, the urinary symptoms were assumed to be caused by SARS-CoV-2, although no viral detection was conducted 68 . In another study, the average International Prostate Symptom Score (IPSS), which is used as a validated questionnaire to quantify lower urinary tract symptoms (LUTS) 69 , was assessed in patients with COVID-19 aged >50 years (n = 62) in the acute stage of the disease and surveyed retrospectively for the time before COVID-19 infection 70 . In the acute stage of COVID-19, the IPSS was significantly higher than before (9 ± 6.4 versus 5.1 ± 4.1, P < 0.0001); no correlation was found between IPSS and radiological degree of pulmonary infiltrates, and no significant differences in IPSS before and during COVID-19 were reported in a group of patients <50 years old (P = 0.053) 70 . Taken together, these results provide clinical evidence that SARS-CoV-2 infection might trigger LUTS, especially in elderly men 70 . The absence of statistically significant differences in IPSS before and during COVID-19 in patients <50 years might be explained by the small sample size of this age group in this study (n = 32) 70 .

Urinary symptoms reported in patients with COVID-19 overlap with common diseases such as benign prostatic hyperplasia; therefore, proving SARS-CoV-2 is the underlying cause is difficult 71 . Searching for possible mechanisms explaining the high prevalence of LUTS in patients with COVID-19, the levels of pro-inflammatory cytokines in urine was assessed in a small study including eight participants (four patients with COVID-19 and de novo urinary tract symptoms and four age-matched participants without COVID-19 and with no history of urinary tract diseases) 72 . The investigators hypothesized that what they called COVID-19-associated cystitis is caused by an increased inflammatory cytokine release into the urine and/or expression in the bladder 72 . Thus, urine samples from patients and age-matched individuals were collected 72 ; all patients positive for COVID-19 (n = 4) had significantly higher levels of IL-6 (P = 0.046) and IL-8 (P = 0.002) in urine than individuals in the COVID-19-negative group (n = 4) 72 . Urinary tract infections can lead to intermittent secretion of IL-6 and IL-8 into the urine 73 ; however, increased interleukin levels in urine are not specific for urinary tract infections at all and might only depend on renal excretion of plasma interleukins.

The detection of SARS-CoV-2 in urine and semen is very rare, but the high prevalence of LUTS in the acute stage of COVID-19 reasonably suggests that the lower urinary tract might still be affected by the virus 67, 68, 70 . Whether the inflammation in the urinary tract of patients with COVID-19 directly depends on SARS-CoV-2 or is secondary to renal excretion of plasma interleukins is still unclear.

Long-term effects of viral orchitis caused by viruses such as mumps, HIV or hepatitis B virus on fertility have been extensively studied 74 . Viral infection of the testes can result in a reduction of sperm quality and endocrine function, and possible long-term effects include oncogenic outcomes or vertical transmission of virus-induced mutations 75 . Understanding how SARS-CoV-2 will affect male fertility has received widespread attention. A survey in multiple European countries showed that 38-58% of individuals who had planned to have a baby Nature reviews | Urology in 2020 were going to postpone this decision 76 , although expected financial challenges caused by the pandemic was the main reason for this choice.

ACE2 expression levels in testes are amongst the highest in the body 77 ; ACE2 can be found in Sertoli cells, Leydig cells and cells of the seminiferous ducts 78 . In vitro cell-binding assays showed that SARS-CoV-2 can also bind to ACE2 on the surface of these cells 53, 78 . Results from histopathological assessment of testicular and epididymal specimens of six deceased men with COVID-19 showed the presence of interstitial oedema, congestion and red blood cell exudation, which were absent in the group of deceased men without COVID-19 (ref. 79 ). Furthermore, thinning of seminiferous epithelium was observed in deceased patients with COVID-19, and the proportion of apoptotic cells in testes of these patients was significantly higher (2.95-fold, P = 0.018) than the average of deceased men without COVID-19. However, no data on histopathological changes in patients with non-fatal COVID-19 are available; therefore, whether the alterations in testes are a general consequence of COVID-19 or exclusively occur in patients with fatal COVID-19 is still unclear.

In another study, SARS-CoV-2 could be detected in testis tissue samples from deceased patients with COVID-19 (n = 6) by transmission electron microscopy, and the density of ACE2 receptors (quantified through immunofluorescence) was reported to be inversely proportional to the level of spermatogenesis, defined as impaired if full spermatogenesis was not visualized in all observed tubules 80 . The direct association between increased ACE2 levels and impairment of spermatogenesis supports the hypothesis that organs with high ACE2 levels are at a high risk of cell damage and suggests that the testes might be target organs of SARS-CoV-2. In another study, results from ten autopsies performed on deceased men with COVID-19 (median age: 49.5 years) revealed morphological testes alterations in 70% of patients, attributable to oxidative stress, as well as sloughing of spermatocytes, elongation of spermatids, swelling of Sertoli cells and multifocal microthrombi 81 .

Testes seem to also be affected in in men with non-fatal COVID-19. In a cross-sectional testicular ultrasonography study, incidental epididymitis was found in 42% of patients with mild-to-moderate COVID-19, all of whom had no scrotal complaints and no clinical signs of orchitis 82 . In another study evaluating the potential association between COVID-19 and testicular pain or epididymo-orchitis in 91 patients with COVID-19, 11% of patients reported scrotal pain 83 . These results suggest that COVID-19 can affect testis and epididymis in the acute stage of the infection, although these effects might be clinically inapparent in many instances.

Effects of SARS-CoV-2 infection on sperm quality also seem to be of concern. Results from a study including 23 patients with COVID-19 and 22 age-matched healthy men showed oligozoospermia (mean ratio: 0.29 (95% CI 0.12-0.71, P = 0.008)) and a significant increase in leukocytes (P = 0.006) in semen of patients with COVID-19 compared with the healthy participants group 79 . In another study, impaired sperm quality in patients with COVID-19 was attributed to recurrent fever 81 , which has been shown to have a detrimental effect on sperm quality 84 , potentially owing to the thermal dependence of spermatogenesis 85, 86 . In a prospective, observational study, sperm quality after recovery from COVID-19 was assessed using the WHO criteria. Sperm parameters were evaluated at three different time points after the infection: short (0-31 days, n = 35); intermediate (32-62 days, n = 51); and long (≥63 days, n = 34) 87 . Mean progressive sperm motility was reduced in 60%, 37% and 28% of men in the short, intermediate and long follow-up time groups, respectively, whereas mean sperm count was reduced in 37%, 29% and 6% of patients in the three groups, respectively 87 . The authors concluded that the estimated recovery time of sperm quality after COVID-19 infection is 3 months, but further follow-up studies are needed to determine whether a minority of men might suffer from permanent testicular damage 87 . The severity of COVID-19 infection (for example, the need to be hospitalized) and the presence of fever did not correlate with sperm characteristics in this study 87 . The effect of COVID-19 on fertility potential in the acute stage of the infection was assessed in a multicentre study including 69 patients aged 20-45 years who previously had COVID-19 but had recovered at least 3 months earlier 88 . Sperm motility and vitality significantly decreased (P ≤ 0.03) in these patients after COVID-19 infection compared with the values from a spermiogram analysis performed in the same patients within the year before SARS-CoV-2 onset. These results could indicate that the estimated recovery time of sperm quality after COVID-19 infection might be longer than the 3 months previously suggested 87 . In another study, men recovering from COVID-19 (n = 30, median age: 40 years) showed a lower total sperm number than age-matched healthy men 89 . In a follow-up analysis (median time: 3 months), the total sperm number in 5 of these 30 men was similar to that reported in the acute phase of COVID-19 (ref. 89 ). No data on the sperm quality in these men before COVID-19 infection are available; therefore, the possibility of a low sperm count before COVID-19 infection exists. In another study, sperm quality was assessed in 74 men aged between 20 and 50 years, who were recovering from COVID-19 (two consecutive negative pharyngeal swab PCR tests were required for inclusion) 90 . Urine, expressed prostatic secretion and semen were analysed for SARS-CoV-2 detection, and the PCR was negative in all the samples collected in all patients. Semen characteristics, including semen volume, total sperm number, sperm concentration, vitality, progressive motility and total (progressive plus non-progressive) motility, were compared with the WHO reference values (based on data from a fertile population and generated from men whose partners had a time to pregnancy ≤12 months) 91 . The total sperm count and total sperm motility in patients with COVID-19 were lower than age-matched healthy men (total sperm count: 197 million versus 261 million, P = 0.0211; total motility: 48.9% versus 56.4%, P < 0.0001), but still above the lower reference limit released by the WHO (total sperm count: 39 million per ejaculate (95% CI 33-46), total sperm motility: 40% (95% CI 38-42)) 90 . Furthermore, patients with a recovery www.nature.com/nrurol time from COVID-19 of ≥90 days had a significantly lower total sperm count than patients who recovered in less than 90 days (152 million versus 224 million, P = 0.0369) 90 . These results suggest that no substantial long-term threats on male fertility after recovery from COVID-19 exist, but the effect of COVID-19 on fertility might be worse for men with a long recovery time than for men who recover within a short time frame.

COVID-19 infection is also associated with endocrine imbalances 92, 93 . In a cohort study including 286 patients with COVID-19 and 281 healthy individuals, significantly lower levels of total testosterone were found in men with COVID-19 at hospital admission than in healthy participants (2.5 nmol/l versus 10.4 nmol/l, P < 0.0001) 92 . In detail, hypogonadism (defined as total testosterone <9.2 nmol/l) was observed in 89.8% of patients with COVID-19, and in only 14.9% of healthy individuals 92 . Most patients (85%), showed secondary hypogonadism (hypogonadotropic hypogonadism, total testosterone <9.2 nmol/l and luteinizing hormone (LH) ≤9.4 mUI/ml) 92 (fig. 3 ). These results indicate that, although the testes might be heavily affected by a SARS-CoV-2 infection under other circumstances 79, 81 , in these patients, the cause of the imbalances in total testosterone levels lies in the central nervous system, as secondary hypogonadism indicates a problem in the pituitary gland or hypothalamus 94 . Results from the univariate analysis showed that total testosterone levels were inversely associated with increased risk of ICU admission (OR 0.54, P < 0.0001) or death (OR 0.68, P < 0.002) 92 . Thus, in these patients, SARS-CoV-2 infection is associated with low total testosterone levels, mostly secondary hypogonadism, and total testosterone correlates with COVID-19 severity 92 . Male hormone levels vary tremendously through acute illness or stress 95 ; therefore, these results should be interpreted with caution. Moreover, in a prospective cohort study in which patients with COVID-19 (n = 89) were compared with patients with non-COVID-19 respiratory tract infection (n = 30) and age-matched healthy individuals (n = 143), total testosterone levels were decreased in patients with COVID-19, but also in patients with non-COVID-19 respiratory tract infections 93 , indicating that the observed hormonal imbalances might be a general phenomenon of critical illness, non-specific for SARS-CoV-2 infection 95 . In another study, the levels of follicle-stimulating hormone (FSH) 96 , LH, testosterone and oestradiol in 74 men aged between 20 and 50 years who were recovering from COVID-19 were reported to be within the normal range 90 . However, opposite results were reported from a study including 121 men who recovered from COVID-19: at a 7-month follow-up time, 55% of men still suffered from hypogonadism (total testosterone <9.2 nmol/l) 97 . Thus, a substantial effect of COVID-19 on the hormonal balance is observed during the acute phase of the infection, but whether this imbalance has long-term repercussions for the total testosterone balance is still unclear 90, 97 .

Analysis of the effects of COVID-19 infection on male reproductive health through histopathological examinations showed that testicular tissue can be severely damaged by SARS- CoV-2 infection 79,81 (fig. 4) .

However, the observed reduced sperm quality in patients in the acute stage of COVID-19 could also be attributed to fever 84, 98 , and long-term data on sperm quality after recovery from COVID-19 are still very limited. Regarding hormonal modifications induced by COVID-19, a reduction in testosterone levels can be found regularly in patients with COVID-19 (refs 92,93 ); secondary hypogonadism is the most frequently observed form of hormonal imbalance, indicating a disturbance in the central nervous system, rather than in the testes 92 . However, contradictory evidence makes it difficult to understand whether or not hormonal imbalance in patients recovering from COVID-19 is only a temporary phenomenon of the acute stage of infection 90, 97 .

Testosterone and androgen deprivation therapy A higher mortality rate for COVID-19 in men than in women has been reported in multiple studies 99, 100 . Moreover, disease severity of COVID-19, measured by hospitalizations and ICU admissions, is higher in men than in women, a phenomenon already observed in previous coronavirus epidemics (SARS-CoV, 2002, and Middle East respiratory syndrome-related coronavirus (MERS), 2012) 101 . Sex disparities in the observed severity of COVID-19 are most likely multifactorial and could partly be explained by different comorbidities and behaviours 101 . Men might be more vulnerable to infections than women owing to biological causes (including immunological, hormonal and genetic differences) and a worse overall health status 102 ; the higher prevalence of smoking in men than in women might also predispose to worse COVID-19 outcomes 102 . Testosterone has also been hypothesized to have a role in sex differences in COVID-19 outcomes, as it regulates ACE2 and TMPRSS2 expression 103, 104 . The link between testosterone and COVID-19 symptoms could also explain why children, who generally exhibit lower expression levels of androgen receptor, show fewer COVID-19 symptoms than adults 105 . Furthermore, androgen-dependent prostate cancer cells highly express TMPRSS2 (a key mediator in viral invasion 20 ) in response to androgens 23 . Thus, in the early stages of the pandemic, treatment with androgen deprivation therapy (ADT) 32 in men with prostate cancer was hypothesized to be protective against COVID-19 infection 106 . In a large population-based study including 4,532 men with 19) and 281 healthy individuals, lower levels of testosterone were found in men with COVID-19 at hospital admission than in healthy participants 92 . In most patients, secondary hypogonadism was observed (luteinizing hormone ≤9.2 mUI/ml).

confirmed SARS-CoV-2 infection, patients with prostate cancer who received ADT were at a significantly lower risk of infection than patients with prostate cancer without ADT (OR 4.05, 95% CI 1.55-10.59, P = 0.0043) or patients with any other malignancy (OR 4.86; 95% CI 1. 88-12.56 , P = 0.0011) 107 . The authors attributed the protective effect of ADT to its ability to decrease TMPRSS2 levels 108 , which has an important role in the fusion process of cellular and viral membranes 20 , and to a reduction of the risk of a cytokine storm by decreasing the number and function of circulating neutrophils 107, 109 . However, results from another study including 1,779 men with prostate cancer reported opposite findings: no significant differences in the number of SARS-CoV-2 infections were observed between patients treated with ADT (5.6%) and patients who did not receive ADT (5.8%; OR 0.93, 95% CI 0.54-1.61, P = 0.8) 110 . Risk factors known to increase SARS-CoV-2 infection and disease severity (such as diabetes, asthma or immune suppressive diseases) 102, 111, 112 were equally distributed between the two cohorts, although men receiving ADT were marginally older (75.5 versus 73.8 years, P = 0.009), more likely to have smoked (68.1% versus 59.3%, P = 0.005) and had more likely taken steroids (43.8% versus 23.3%, P < 0.001) than patients with prostate cancer not treated with ADT 110 . These contradictory findings might be explained by the anti-inflammatory properties of testosterone 113, 114 , which could also explain why men with COVID-19 and high levels of testosterone (≥2.9 ng/ml total testosterone at hospital admission) test positive for SARS-CoV-2 for a shorter time frame than those with total testosterone levels of <2.9 ng/ml (median time to negative PCR test: 26 days versus 18 days; P = 0.002) 115 . Low total testosterone levels in men have been associated with hyper-inflammatory syndrome and respiratory failure 116 , and total testosterone levels are inversely associated with increased risk of ICU admission or death 92 ; thus, the (most probably transitory) hypogonadism caused by SARS-CoV-2 infection was suggested to promote severe outcomes 92 . In the COVIDENZA trial, including men and women >50 years old, the effect of the inhibition of testosterone signalling through enzalutamide on the outcome of hospitalized patients with COVID-19 was evaluated 117 . Overall, 42 patients were enrolled and randomized 2:1 to receive 5 days of treatment with enzalutamide or standard of care 117 . Patients treated with enzalutamide required longer hospitalization (hazard ratio for discharge from hospital: 0.43, 95% CI 0.20-0.93) than patients treated with the standard of care 117 . The trial was terminated early and the authors concluded that androgen inhibition should not be used for prevention or treatment of COVID-19 (ref. 117 ).

In conclusion, evidence suggests that testosterone could be associated with higher COVID-19 disease severity in men than in women [102] [103] [104] . However, the exact effect of testosterone on COVID-19 severity and the underlying mechanisms are still unclear, as reflected in the contradictory findings about the effect of ADT on the risk of SARS-CoV-2 infection 107, 110 Seminiferous tubules Straight tubules

Detected in only ~4% of tested patients Fig. 4 | Effects of SArS-CoV-2 on male reproductive health. In a testicular ultrasonography study, incidental epididymitis was found in 42% of patients with mild-to-moderate coronavirus disease 2019 (COVID-19) 82 . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be detected in semen, but this event is rare [61] [62] [63] [64] [65] . Oligozoospermia, reduced sperm motility and sperm vitality, as well as leukocytospermia, are reported frequently in the acute phase of COVID-19 infection 79, 87, 90 . Testicular tissue can be severely damaged by SARS-CoV-2 infection, leading to a wide range of pathological changes in autopsy studies 79, 81 . Angiotensin-converting enzyme 2 (ACE2) expression levels in testes are amongst the highest in the body 77 

www.nature.com/nrurol Urological thromboembolic complications Thromboembolism is a frequent and severe complication of COVID-19 (ref. 118 ). A study including 184 patients with COVID-19 pneumonia in the ICU reported a remarkably high incidence of thromboembolic complications in these patients (31%), including deep vein thrombosis or pulmonary embolism 119 . In a meta-analysis of 49 studies including 18,093 patients with COVID-19, the reported pooled incidence was 17.0% for venous thromboembolism and 7.1% for pulmonary embolism 120 ; the incidence of venous thrombo embolism was higher in studies that used systematic screening than in those relying on clinical diagnosis (33.1% versus 9.8%, P < 0.0001) 120 . However, in a study including 256 patients with COVID-19 pneumonia and 360 patients with non-COVID-19 pneumonia, the rate of venous thromboembolism was not significantly different between the two groups (2% versus 3.6% respectively, P = 0.229), indicating that the observed hypercoagulable state in patients with COVID-19 might not be dependent on SARS-CoV-2 (ref. 121 ). How ever, the underlying mechanisms of thromboembo lism in patients with COVID-19 seem to be different from COVID-19-independent thromboembolism. COVID-19associated coagulopathy seems to be mediated by excessive inflammation, endothelial activation and injury, platelet activation, impaired or dysfunctional fibrinolysis and systemic hypercoagulability 122 ; vascular endothelial cells are among the primary targets of SARS-CoV-2, and COVID-19 infection can result in endothelial damage and also in systemic vasculitis 123 . COVID-19associated coagulopathy is probably a multi factorial combination of low-grade disseminated intravascular coagulation, thrombotic microangiopathy and released pro-inflammatory cytokines such as IL-6, which can induce tissue factor expression on mono nuclear cells and subsequently initiate coagulation activation and thrombin generation 124 . COVID-19-associated coagulopathy is characterized by an isolated elevation of D-dimer (a degradation product from fibrin used as a biomarker of coagulation and fibrinolysis 125 ) and is associated with disease severity and numerous thrombotic complications 123 . Differently from sepsis-induced disseminated intravascular coagulation, alter ations in platelet counts, prothrombin time and partial thromboplastin time are uncommon in the initial presentation of patients with COVID-19-associated coagulopathy 126 .

Repercussions of thromboembolism in the genitourinary tract of patients with COVID-19 have also been observed, and include a patient with prostate infarction and several patients with renal infarction associated with COVID-19 (refs 127-131 ). Moreover, ischaemia-related priapism was reported as a thromboembolic complication in a 62-year-old patient with COVID-19 (ref. 132 ). However, no clear proof indicating that these thromboembolism effects are directly caused by SARS-CoV-2 is currently available.

In summary, thromboembolism is a frequent complication of COVID-19 (ref. 118 ) and also affects organs of the genitourinary tract [127] [128] [129] [130] [131] [132] . The incidence of thromboembolism in patients with COVID-19 is similar to that observed in non-COVID-19 pneumonia 121 , but the pathophysiological background seems to be completely different 123, 124, 126 .

Outlook for COVID-19 pandemic Variants of concern are steadily replacing the wild-type form of SARS-CoV-2, but vaccination programmes are in place and compete in a neck-and-neck race. People avoiding hospitals during the pandemic might be the cause of decreased overall survival in patients with uro-oncological malignancies, owing to missed diagnoses or delayed treatments.

Variants of concern. COVID-19 variants have the potential to substantially increase mortality. In a retrospective cohort study including 212,326 patients with COVID-19, patients with variants of concern (including Alpha/ B1.1.17, Beta/B.1.351 and Gamma/P.1) were at a higher risk of hospitalization (OR 1.52 (95% CI 1.42-1.63)), ICU admission (OR 1.89 (95% CI 1.67-2.17)) and death (OR 1.51 (95% CI 1.30-1.78)) than patients with non-variant of concern SARS-CoV-2 strains 133 134, 135 . The effects of the new COVID-19 variants on the risk of developing urological complications in patients with COVID-19 still need to be assessed.

Vaccines for COVID-19 are considered an essential part of the strategy for ending the pandemic 136 , but one major reason for COVID-19 vaccine refusal is anxiety about adverse effects 137, 138 . Regarding urology, no evidence of male or female fertility reduction following COVID-19 vaccination has been reported 139 . Results from an analysis of the FDA Vaccine Adverse Event Reporting System showed that <1% of vaccinated people described urological symptoms 140 . Many of the reported symptoms of COVID-19 vaccination (LUTS, haematuria and urinary infection) have the same prevalence in vaccinated and unvaccinated individuals; thus, a causal attribution to the vaccination seems unlikely 140 . In a study analysing sperm parameters before and after COVID-19 mRNA vaccination in 45 men (median age: 28 years) receiving BNT162b2 (Pfizer-BioNTech, 46.7%) or mRNA-1273 (Moderna, 53.3%), no substantial decrease in any sperm parameter was reported 141 . Another reason for vaccine refusal is a misunder standing about vaccine efficacy. Results from a study including three online behavioural experiments involving 1,800 participants showed that vaccine efficacy is constantly confused with the non-incidence rate of COVID-19 in vaccinated people, which leads to an overestimation of the probability of developing COVID-19 (ref. 142 ). The investigators suggested that educational programmes are urgently needed to increase the understanding of vaccine safety and efficacy, which would lead to increased vaccination campaign adherence.

Patients with medical emergencies often avoid hospital emergency departments because of the fear of COVID-19 Nature reviews | Urology 0123456789();: contagion 143 . Urologists are also noticing a delay in consultation in some instances 144 , which could lead to increased morbidity and mortality, particularly in the field of oncology, in which the effect of missed diagnoses and delayed treatments might be devastating 145 . In the UK, 45% of patients with potential cancer symptoms (such as coughing up blood) did not contact their doctor in the first wave of the pandemic 146 . In urology, a dramatic decline in routine prostate cancer screening was observed [147] [148] [149] [150] . A median decrease of 62% in requested total PSA tests was observed during the local lockdown period in Italy (10 March to 17 May 2020) 147 . Results from another study in Italy showed a noticeable decline in cancer diagnoses during the COVID-19 pandemic in 2020, compared with the same period in the previous 2 years, with the greatest decrease observed in prostate cancer and bladder cancer diagnoses (75% and 66%, respectively) 148 . In a cancer screening study from the USA including 192,060 patients, the decrease in PSA testing during the first peak of the pandemic (2 March to 2 June 2020) was ≥60% compared with three periods of time before and after the peak 149 . In Sweden, the number of men diagnosed with prostate cancer decreased by one-third in spring 2020 compared with previous years, but no reduction in the number of curative treatments was observed 150 . A severe increase in the number of avoidable cancer deaths owing to COVID-19-induced lockdowns is still expected 151 .

End of the pandemic. The perspective of when the COVID-19 pandemic will end is mainly influenced by two factors: the progress of vaccine programmes and the spread of variants of concern 152 . The spread of the Delta variant caused a set-back for high-income countries in the race to reach herd immunity 152, 153 . However, the Omicron variant induces a considerably milder disease at the population level and has been shown to trigger crossprotective immunity towards the Delta variant 135 . The transition of COVID-19 to an endemic disease might be a more realistic end point than herd immunity 152 , but countless unpredictable variables make any serious prediction impossible. COVID-19 might truly become endemic only when most adults have developed natural immunity by having been exposed to the virus multiple times as children 154 . This process might take decades; thus, until this point, a judgement call on how vulnerable people can be protected and how many deaths society is willing to tolerate is needed 154 . Vaccine development and also research into the mechanisms and effects of SARS-CoV-2 infection in different organs are crucial to get a realistic chance of managing this disease efficiently, thereby bringing the pandemic to an end.

In March 2020, the WHO declared the COVID-19 outbreak a pandemic. Since then, a considerable number of studies describing the effects of SARS-CoV-2 infection in different organs have been published. Urology soon Binding of the viral spike proteins to ACE2 receptors on the host cell surface enables cellular entry of SARS-CoV-2 virus. Kidney proximal tubule cells, bladder urothelial cells and testes show high ACE2 expression levels.

AKI is frequently reported in patients with COVID-19 (1-46%). Severe structural changes in kidneys from patients with COVID-19 can be found in pathological examinations, and underlying mechanisms include cytokine storm-induced SIRS and direct cytopathic effects.

Increased urinary frequency, nocturia and IPSSs were reported in patients with COVID-19.

Detection of SARS-CoV-2 in urine is rare (<5% of patients), but can persist up to 52 days after disease onset.

Secondary hypogonadism was found in 85% of patients with COVID-19, but the possible effect of testosterone levels on survival is controversial.

Histopathological analysis of testes from patients with COVID-19 showed noticeable changes like interstitial oedema, focal atrophy and red blood cell exudation. SARS-CoV-2 was detected in testis tissues by transmission electron microscopy, but, in most studies, it could not be detected in semen. Low sperm count and low total sperm motility have been reported in patients with COVID-19.

Thromboembolism is a major complication of COVID-19 and has been reported in 31% of patients in the ICU with COVID-19 pneumonia. Prostate and renal infarction, as well as priapism, were reported as thromboembolic complications. www.nature.com/nrurol emerged as a focus of interest, owing to a potential threat of long-term damage induced by COVID-19 to kidney function, fertility and hormonal balance. ACE2 expression in different tissues is hypothesized to correlate with the risk of viral invasion, and results from several studies reported high expression levels of ACE2 in the genitourinary tract. AKI is a severe urological complication of COVID-19 accompanied by high mortality, which is hypothesized to be caused by a cytokine-storm-induced systemic inflammatory response and direct cytopathic effects. The detection of SARS-CoV-2 in urine and semen is very rare; however, a possible risk of transmission through these body fluids has not yet been ruled out. Viral orchitides are accepted to lead to a reduction in fertility and endocrine function; therefore, the effects of SARS-CoV-2 on male fertility seem to be a main focus of interest. Results from autopsy studies on patients with COVID-19 revealed severe structural changes in testes, and, in several studies on semen samples, an impairment of spermatogenesis was reported in patients with COVID-19. However, these effects might also be attributed to fever, and long-term data on sperm quality after recovery from COVID-19 are still very limited. Low levels of testosterone were also detected frequently in men with COVID-19, and, in most instances, hypogonadism was secondary. An intense discussion on the role of testo sterone in the high prevalence of severe COVID-19 complications is in place. Low total testosterone levels are associated with poor outcomes; however, whether hypogonadism is caused by SARS-CoV-2 infection or is just a general phenomenon of critical illness is still unclear. Thromboembolic complications, which are frequent in COVID-19, also affect urogenital organs.

Long-term effects of COVID-19 cannot yet be fully evaluated, but understanding how SARS-CoV-2 causes injury in genitourinary organs and defining risk factors associated with severe damage of these organs is crucial for developing strategies to protect patients with COVID-19 from urological complications. To date, high-quality evidence of these pathophysiological processes in the urogenital system is limited. Published studies on the effect of COVID-19 on the urogenital tract often have a small sample size and, in some cases, reported heterogeneous results. Moreover, many urological symptoms overlap with common diseases and, therefore, a causal attribution to SARS-CoV-2 is difficult to prove. Some clinical manifestations might not be directly caused by SARS-CoV-2, but could be secondary effects induced by an excessive immune response or cardiorespiratory impairment; thus, further exploration with prospective studies and large cohorts is urgently needed.

In summary, published data made one point clear: COVID-19 is also a urological matter ( fig. 5 ) and urologists must learn to detect and manage short-term and long-term damage to the genitourinary tract caused by COVID-19 for the benefit of patients.

Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel

The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

WHO. Novel Coronavirus(2019-nCoV) Situation Report -22

Extrapulmonary manifestations of COVID-19

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European pulmonary pathologists

Autopsy findings in COVID-19-related deaths: a literature review

Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management

COVID-19 and the liver: overview

Coronavirus disease-2019 (COVID-19) and the liver

COVID-19 and acute pancreatitis: examining the causality

COVID-19 myocarditis and long-term heart failure sequelae

Encephalopathy in patients with COVID-19: a review

European Observatory on Health Systems and Policies. In the wake of the pandemic: Preparing for Long COVID (World Health Organization

Characterising long COVID: a living systematic review

Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Multiple expression assessments of ACE2 and TMPRSS2 SARS-CoV-2 entry molecules in the urinary tract and their associations with clinical manifestations of COVID-19

Mechanisms of SARS-CoV-2 entry into cells

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

TMPRSS2 and COVID-19: serendipity or opportunity forintervention? Cancer Discov

Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway

Prostate-localized and androgenregulated expression of the membrane-bound serine protease TMPRSS2

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis

COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

Controversial roles of the renin angiotensin system and its modulators during the COVID-19 pandemic

The emerging role of ACE2 in physiology and disease

The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science

The reninangiotensin-aldosterone system and coronavirus disease 2019

COVID-19 and the kidney: what we think we know so far and what we don't

AKI in hospitalized patients with COVID-19

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study

Kidney disease is associated with inhospital death of patients with COVID-19

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

Acute kidney injury in patients hospitalized with COVID-19

Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020

Acute kidney injury in COVID-19: are kidneys the target or just collateral damage? A comprehensive assessment of viral RNA and AKI rate in patients with COVID-19

Association between chronic kidney disease and COVID-19-related mortality in New York

Kidney biopsy findings in patients with COVID-19

Postmortem kidney pathology findings in patients with COVID-19

Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases

A multi-center retrospective cohort study defines the spectrum of kidney pathology in coronavirus 2019 disease (COVID-19)

APOL1 and kidney disease: from genetics to biology

Pathology of COVID-19-associated acute kidney injury

Cytokine storm

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The pathogenesis and treatment of the 'cytokine storm

The COVID-19 cytokine storm; what we know so far

Bacteriuria in patients with an orthotopic ileal neobladder: urinary tract infection or asymptomatic bacteriuria?

A deep look into COVID-19 severity through dynamic changes in blood cytokine levels

ACE2 expression in kidney and testis may cause kidney and testis infection in COVID-19 patients

Expression profiles revealed potential kidney injury caused by SARS-CoV-2: a systematic analysis of ACE2 and clinical lessons learned from this discovery

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19

Urinary viral shedding of COVID-19 and its clinical associations: a systematic review and meta-analysis of observational studies

Anal swab as a potentially optimal specimen for SARS-CoV-2 detection to evaluate hospital discharge of COVID-19 patients

No detection of SARS-CoV-2 RNA on urethral swab in patients with positive nasopharyngeal swab

A systematic review on the investigation of SARS-CoV-2 in semen

Presence of SARS-CoV-2 RNA in semen -cohort study in the United States COVID-19 positive patients

Clinical characteristics and results of semen tests among men with coronavirus disease 2019

Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19

SARS-CoV-2 RNA shedding in semen and oligozoospermia of patient with severe coronavirus disease 11 weeks after infection

COVID-19 may affect male fertility but is not sexually transmitted: a systematic review

Urinary frequency as a possibly overlooked symptom in COVID-19 patients: does SARS-CoV-2 cause viral cystitis?

De novo urinary symptoms associated with COVID-19: COVID-19-associated cystitis

The American Urological Association Symptom Index for Benign Prostatic Hyperplasia

The effect of COVID-19 on lower urinary tract symptoms in elderly men

COVID-19: importance of the awareness of the clinical syndrome by urologists

COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC)

The mucosal cytokine response to urinary tract infections

Viral threat to male fertility

Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol

The impact of COVID-19 on fertility plans in Italy

Bioinformatic and mouse model reveal the potential high vulnerability of Leydig cells on SARS-CoV-2

Single-cell transcriptome analysis of the novel coronavirus (SARS-CoV-2) associated gene ACE2 expression in normal and non-obstructive azoospermia (NOA) human male testes

Impaired spermatogenesis in COVID-19 patients

Histopathology and ultrastructural findings of fatal COVID-19 infections on testis

Testicular changes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Radiological patterns of incidental epididymitis in mild-to-moderate COVID-19 patients revealed by colour Doppler ultrasound

Is there any association of COVID-19 with testicular pain and epididymo-orchitis?

History of febrile illness and variation in semen quality

High risk of temporary alteration of semen parameters after recent acute febrile illness

The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men

Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test

Short-term effects of COVID-19 on semen parameters: a multicenter study of 69 cases

Evaluation of SARS-CoV-2 in human semen and effect on total sperm number: a prospective observational study

No detection of SARS-CoV-2 from urine, expressed prostatic secretions, and semen in 74 recovered COVID-19 male patients: a perspective and urogenital evaluation

World Health Organization reference values for human semen characteristics

Severely low testosterone in males with COVID-19: a case-control study

SARS-CoV-2 pneumonia affects male reproductive hormone levels: a prospective, cohort study

Part II: etiology, pathophysiology, and diagnosis

Altered gonadal steroidogenesis in critical illness: is treatment with anabolic steroids indicated?

Outpatient urine culture: does collection technique matter?

Testosterone in males with COVID-19: a 7-month cohort study

Investigation of SARS-CoV-2 in semen samples and the effects of COVID-19 on male sexual health by using semen analysis and serum male hormone profile: a cross-sectional, pilot study

The role of sex in the risk of mortality from COVID-19 amongst adult patients: a systematic review

Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area

Sex-based differences in severity and mortality in COVID-19

Are sex disparities in COVID-19 a predictable outcome of failing men's health provision?

Androgen signaling regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and MPRSS2

COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor

COVID-19 and androgentargeted therapy for prostate cancer patients

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N=4532)

The early effects of rapid androgen deprivation on human prostate cancer

Sex differences in immune responses

Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19-related outcomes in immunocompromised patients: a nationwide study in Korea

Do androgens modulate the pathophysiological pathways of inflammation? Appraising the contemporary evidence

The effects of sex hormones on immune function: a meta-analysis

Modeling the contribution of male testosterone levels to the duration of positive COVID testing among hospitalized male COVID-19 patients

Role of testosterone in SARS-CoV-2 infection: a key pathogenic factor and a biomarker for severe pneumonia

A phase 2 trial of the effect of antiandrogen therapy on COVID-19 outcome: no evidence of benefit, supported by epidemiology www.nature.com/nrurol 0123456789();: and in vitro data

Venous thromboembolism in COVID-19: a systematic review and meta-analysis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis

Comparison of venous thromboembolism risks between COVID-19 pneumonia and communityacquired pneumonia patients

Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

The coagulopathy, endotheliopathy, and vasculitis of COVID-19

Coagulation abnormalities and thrombosis in patients with COVID-19

Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis

COVID-19 and its implications for thrombosis and anticoagulation

Is prostate infarction and acute urinary retention a possible complication of severe COVID-19 infection?

Kidney infarction in patients with COVID-19

Case report: COVID-19 associated renal infarction and ascending aortic thrombosis

Renal infarction in COVID-19 patient

Bilateral renal infarction in a patient with severe COVID-19 infection

Priapism in a patient with coronavirus disease 2019 (COVID-19)

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada

Omicron's feeble attack on the lungs could make it less dangerous

Milder disease with Omicron: is it the virus or the pre-existing immunity?

Vaccines for COVID-19

Evaluation of COVID-19 vaccine refusal in parents

Vaccine hesitancy in the era of COVID-19

Covid-19: no evidence that vaccines can affect fertility, says new guidance

Low rates of urologic side effects following COVID vaccination: an analysis of the FDA vaccine adverse event reporting system

Sperm parameters before and after COVID-19 mRNA vaccination

The misunderstanding of vaccine efficacy

Where are all the patients? Addressing Covid-19 fear to encourage sick patients to seek emergency care

The invisible impact of COVID-19: indirect mortality in urology

The Lancet Oncology. COVID-19 and cancer: 1 year on

Cancer symptom experience and help-seeking behaviour during the COVID-19 pandemic in the UK: a cross-sectional population survey

Is COVID-19 impacting prostate cancer screening? A survey of prostate-specific antigen test requests during a local outbreak

Cancer diagnostic rates during the 2020 'lockdown', due to COVID-19 pandemic, compared with the 2018-2019: an audit study from cellular pathology

Cancer screening tests and cancer diagnoses during the COVID-19 pandemic

Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scand

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

When will the COVID-19 Pandemic End? McKinsey & Company

Five reasons why COVID herd immunity is probably impossible

Will Omicron end the pandemic? Here's what experts say

B.E., G.M., Y.V. and J.-N.M. researched data for the article. B.E. and G.M. wrote the article. Y.V., G.M. and C.G.S. made a substantial contribution to discussion of the content. All authors reviewed and edited the manuscript before submission.

The authors declare no competing interests

Nature Reviews Urology thanks A. Kadioglu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.